Fig. 1 · Structure

Documents & Downloads

Gedatolisib (PKI-587)

Cat. No. A11079 CAS 1197160-78-3

PI3K/mTOR inhibitor

Gedatolisib (PKI-587) is a highly potent PI3K/mTOR kinase inhibitor that inhibits PI3K-α,β,γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively.

In Stock

Publications for Gedatolisib

1 publication citing this product

  1. Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Gedatolisib (PKI-587) showed cellular PI3K/mTOR pathway suppression in canine MegTCC cells, reducing Akt, 4E-BP1 and p70S6K phosphorylation after 24 h. LCTCC cells did not show comparable sustained changes under the same dose-response design, illustrating model-dependent activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PI3Kα (Cell-free assay) 0.4 nM
mTOR (Cell-free assay) 1.6 nM
PI3Kγ (Cell-free assay) 5.4 nM

Cellular Effect

Cell Line Activity Value Description Reference
A-431 IC50 0.06 μM Antiproliferative activity against human A431 cells harboring wild type EGFR mutant assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay [PMID: 34971874]
BaF3 IC50 0.1 μM Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M/C797S mutant assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay [PMID: 34971874]
CNE-2 IC50 0.2 μM Antiproliferative activity against human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
HCT-116 IC50 0.51 μM Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
HeLa IC50 5.51 μM Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
HepG2 IC50 14.76 μM Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
L02 IC50 27.33 μM Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
MCF7 IC50 0.37 μM Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
MDA-MB-231 IC50 1.08 μM Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 34971874]
MDA-MB-361 IC50 < 10 nM Inhibition of Akt S473 phosphorylation in human MDA-MB-361 cells by Western blotting [PMID: 20166697]
MDA-MB-361 IC50 3 nM Growth inhibition of human MDA-MB-361 cells after 72 hrs [PMID: 21763134]
MDA-MB-361 IC50 8 nM Inhibition of Akt T308 phosphorylation in human MDA-MB-361 cells by Western blotting [PMID: 20166697]
NCI-H1975 IC50 0.115 μM Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by celltiter-glo assay [PMID: 34971874]
PC-3 IC50 11 nM Growth inhibition of human PC3 cells after 72 hrs [PMID: 21763134]
Sf9 IC50 0.4 nM Inhibition of human PI3Kalpha expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay [PMID: 21763134]
Sf9 IC50 11 nM Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay [PMID: 21763134]

16 records · Scroll to view more

Gedatolisib (PKI-587) Research Summary

This section summarizes 3 in vitro studies and 3 in vivo studies of Gedatolisib (PKI-587) from 3 published references. In vitro models include canine transitional-cell carcinoma lines MegTCC and LCTCC.

Gedatolisib (PKI-587) In Vitro Studies

In a 96-h WST-1 assay across 12 canine tumor cell lines, gedatolisib had IC50 values below 1 µM in 10 lines. Responses varied substantially, and the study did not establish efficacy or tolerability in dogs. [1]

Across 28 breast-cancer cell lines treated for 72 h, gedatolisib produced an average GR50 of 12 nM and GRMax of −0.68. Its average growth-rate response exceeded those of alpelisib, capivasertib and everolimus in this panel; these cellular metrics do not establish comparative clinical efficacy. [2]

Canine tumor-cell viability panel

Cell-based study · 12 canine cell lines from six tumor types: POS, HMPOS, MCTCC, LCTCC, MegTCC, MomoTCC, CMeC, MCM-N1, DH82, CHS-4, CoMS and CLAC. [1]

Gedatolisib reduced the WST-1 viability endpoint; IC50 values were <1 µM in 10 of 12 lines. Sensitivity was heterogeneous. CLAC was below 50% viability even at the lowest tested concentration, and its plotted IC50 was a boundary placeholder rather than an exact fitted potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability after 96 hIC50 <1 µM in 10 of 12 cell lines[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 nM–10 µM
Exposure duration
96 h
Method
WST-1 absorbance assay
Vehicle
0.1% DMSO control
Reported limits
Five replicates are reported; independent-experiment versus well-level replication is not specified in the caption.
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Figure 2A–B and caption; Methods: Inhibitors, Cell viability assay, Statistical analysis; Results: Gedatolisib decreases cell viability

Cell viability after 96 h: Three-parameter variable-slope sigmoidal dose-response fitting; Figure 2A reports mean ± SD of five replicates. — Figure 2A–B and caption; Results first subsection

Differential cellular PI3K/mTOR pathway suppression

Cell-based study · Canine transitional-cell carcinoma lines MegTCC and LCTCC. [1]

After 24 h, dose-dependent loss of Akt, 4E-BP1 and p70S6K phosphorylation and increased p27Kip1 were reported in MegTCC; comparable sustained changes were not detected in LCTCC. This is cellular pathway evidence, not a direct enzyme-binding or selectivity assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Akt (Ser473), 4E-BP1 (Thr37/46), p70S6K (Thr389) phosphorylation and p27Kip1 expressionQualitative immunoblot response Dose-dependent suppression in MegTCC; no comparable changes detected in LCTCC at 24 h[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 nM–10 µM shown in Figure 4A, plus zero-dose control
Exposure duration
24 h
Method
Immunoblotting of phosphorylated and total proteins with β-actin loading control
Vehicle
0.1% DMSO
Reported limits
Blot replication not specified in the adopted caption; no quantitative band-effect sizes reported.
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Figure 4A and caption; Methods: Inhibitors and Immunoblotting; Results: Gedatolisib inhibits the phosphorylation

Akt (Ser473), 4E-BP1 (Thr37/46), p70S6K (Thr389) phosphorylation and p27Kip1 expression: Phosphorylated/total protein and β-actin bands; no densitometric estimates extracted. — Figure 4A; corresponding Results paragraph

Growth-rate response across breast-cancer cell lines

Cell-based study · 28 human breast-cancer cell lines with varied PIK3CA/PTEN and ER/HER2 status. [2]

Gedatolisib had an average GR50 of 12 nM and average GRMax of −0.68 across the panel after 72 h. It was more potent and efficacious on average than alpelisib, capivasertib and everolimus in this assay. These are growth-rate metrics, not biochemical IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Concentration yielding normalized growth-rate value 0.5 across 28 cell linesAverage GR50 12 nM[2]
Normalized growth rate at maximum tested concentrationAverage GRMax −0.68[2]

Literature-Reported Treatment Conditions

Treatment concentration
1.4–9000 nM
Exposure duration
72 h
Method
RT-Glo MT before and after treatment; proliferation-normalized growth-rate analysis
Vehicle
Matched DMSO control
Reported limits
Figure 1c reports n=2 biologically independent samples; no whole-panel biological replication count is assigned here beyond the caption.
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Figure 1c–f, especially table 1e; Results: Analysis of PAM inhibitors response; Methods: Treatments, Viability and cell death, GR assays

Concentration yielding normalized growth-rate value 0.5 across 28 cell lines: Pre/post-treatment viability and growth-rate curve fitting. — Results first subsection; Figure 1e average row

Normalized growth rate at maximum tested concentration: Negative GR values denote cytotoxicity; pooled panel average, not a percent viability. — Figure 1e average row; Methods: GR assays

Gedatolisib (PKI-587) In Vivo Studies

A clinical formulation of gedatolisib inhibited viable tumor-cell growth in two 7-day breast-cancer mini-PDX capsule models: reported inhibition was 85% in PDX361836 and >60% in PDX362153. Each arm contained six capsules distributed among only two mice, and the assay did not assess long-term tumor control or survival. [2]

Gedatolisib did not significantly deplete disseminated tumor cells in murine T4-2 or MCF-7 breast-cancer models. In the MCF-7 model it did not significantly improve metastasis-free survival, and adding it to doxorubicin/cyclophosphamide did not improve that regimen. The T4-2 study showed a kidney/adrenal signal reduction with monotherapy but no consistent overall benefit; the combination had higher mean brain signal than chemotherapy alone, a nonsignificant difference. [3]

TNBC dissemination model

Animal study · Female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP T4-2 TNBC cells. [3]

Gedatolisib did not significantly reduce lung DTC burden or enhance AC efficacy overall. A kidney/adrenal bioluminescence reduction occurred with monotherapy. Brain burden was higher on average with gedatolisib plus AC, without a statistically significant comparison to AC alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lung disseminated tumor-cell burdenGroup sizes and qualitative effect No significant reduction; n=5 vehicle, n=5 AC, n=7 gedatolisib, n=6 gedatolisib+AC[3]
Kidney/adrenal metastatic bioluminescence versus vehicleP value P = 0.016 for gedatolisib monotherapy[3]
Brain bioluminescence, gedatolisib+AC versus AC aloneReported mean signal and comparison 1451 versus 17 p·s−1·cm−2·sr−1; P = 0.2162[3]

Conditions shared by the study groups

Frequency
Gedatolisib/vehicle priming on day 5; treatment days 7, 14, 21, 28; AC/vehicle 1 h later on treatment days.
Treatment course
Four weekly treatment rounds; day-29 DTC endpoint.
Vehicle
0.3% L-lactic acid and 5% dextrose in water; PBS used for injection-volume balance. AC control vehicle: 5% DMSO, 30% PEG300, 5% Tween in water.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle and AC-only groups as appropriateVehicle comparator[3]
AC chemotherapy
Doxorubicin 2 mg/kg + cyclophosphamide 60 mg/kg
Vehicle and AC-only groups as appropriateAC comparator[3]
Gedatolisib
Gedatolisib 10 mg/kg
Vehicle and AC-only groups as appropriateNo overall DTC-clearance benefit[3]
Gedatolisib plus AC
Gedatolisib 10 mg/kg + doxorubicin 2 mg/kg + cyclophosphamide 60 mg/kg
Vehicle and AC-only groups as appropriateNo enhancement over AC; unfavorable direction on some metastatic endpoints[3]
Vehicle
Model: Female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP T4-2 TNBC cells.
Route: Matched vehicle injections
AC chemotherapy
Model: Female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP T4-2 TNBC cells.
Route: Intraperitoneal AC
Gedatolisib
Model: Female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP T4-2 TNBC cells.
Route: Intravenous gedatolisib
Gedatolisib plus AC
Model: Female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP T4-2 TNBC cells.
Route: Intravenous gedatolisib; intraperitoneal AC
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: PF-05212384

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Results 3.3; Figure 3A–F and caption; Methods 2.4.1, 2.4.4–2.4.6, 2.4.8–2.4.9 and 2.5

Lung disseminated tumor-cell burden: Cleared-lung GFP-positive DTC quantification; mean ± SEM; unpaired two-tailed t-tests. — Figure 3C and caption

Kidney/adrenal metastatic bioluminescence versus vehicle: Ex-vivo organ bioluminescence; two-way ANOVA; mean ± SEM. — Figure 3E and caption

Brain bioluminescence, gedatolisib+AC versus AC alone: Caption supplies rounded means; viewed Figure 3F supplies comparison P value. Mean ± SEM shown; unpaired two-tailed t-test. — Figure 3F image and caption

Vehicle · Results 3.3; Figure 3A–F and caption; Methods 2.4.1, 2.4.4–2.4.6, 2.4.8–2.4.9 and 2.5

AC chemotherapy · Results 3.3; Figure 3A–F and caption; Methods 2.4.1, 2.4.4–2.4.6, 2.4.8–2.4.9 and 2.5

Gedatolisib · Results 3.3; Figure 3A–F and caption; Methods 2.4.1, 2.4.4–2.4.6, 2.4.8–2.4.9 and 2.5

Gedatolisib plus AC · Results 3.3; Figure 3A–F and caption; Methods 2.4.1, 2.4.4–2.4.6, 2.4.8–2.4.9 and 2.5

ER-positive dissemination and metastasis-free survival

Animal study · Ovariectomized female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP MCF-7 ER-positive cells. [3]

Gedatolisib, alone or with AC, did not significantly deplete lung or bone-marrow DTCs. Gedatolisib did not significantly improve metastasis-free survival; AC alone did, while adding gedatolisib did not improve AC.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lung and bone-marrow DTC burden at day 29Group sizes and qualitative effect No significant depletion; n=5 vehicle, n=4 AC, n=4 gedatolisib, n=6 gedatolisib+AC[3]
Metastasis-free survival during 15-week follow-upLog-rank (Mantel–Cox) P values Vehicle vs gedatolisib: P = 0.056; AC vs gedatolisib+AC: P = 0.753; vehicle vs AC: P = 0.002[3]

Conditions shared by the study groups

Frequency
Gedatolisib/vehicle priming on day 5; treatment days 7, 14, 21, 28; AC/vehicle 1 h later on treatment days.
Treatment course
Four weekly treatment rounds; day-29 DTC endpoint; separate 15-week follow-up cohort.
Vehicle
0.3% L-lactic acid and 5% dextrose in water; PBS used for injection-volume balance. AC control vehicle: 5% DMSO, 30% PEG300, 5% Tween in water.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle and AC-only groups as appropriateVehicle comparator[3]
AC chemotherapy
Doxorubicin 2 mg/kg + cyclophosphamide 60 mg/kg
Vehicle and AC-only groups as appropriateAC comparator[3]
Gedatolisib
Gedatolisib 10 mg/kg
Vehicle and AC-only groups as appropriateNo overall DTC-clearance benefit[3]
Gedatolisib plus AC
Gedatolisib 10 mg/kg + doxorubicin 2 mg/kg + cyclophosphamide 60 mg/kg
Vehicle and AC-only groups as appropriateNo enhancement over AC; unfavorable direction on some metastatic endpoints[3]
Vehicle
Model: Ovariectomized female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP MCF-7 ER-positive cells.
Route: Matched vehicle injections
AC chemotherapy
Model: Ovariectomized female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP MCF-7 ER-positive cells.
Route: Intraperitoneal AC
Gedatolisib
Model: Ovariectomized female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP MCF-7 ER-positive cells.
Route: Intravenous gedatolisib
Gedatolisib plus AC
Model: Ovariectomized female athymic Crl:NU(NCr)-Foxn1nu mice with disseminated ffluc-eGFP MCF-7 ER-positive cells.
Route: Intravenous gedatolisib; intraperitoneal AC
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: PF-05212384

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Results 3.4; Figure 4A–G and caption; Methods 2.4.1, 2.4.3–2.4.9 and 2.5

Lung and bone-marrow DTC burden at day 29: GFP-positive DTC quantification in cleared lung and whole-mounted marrow; mean ± SEM; unpaired two-tailed t-tests. — Figure 4C,E and caption

Metastasis-free survival during 15-week follow-up: n=11 vehicle, n=10 AC, n=6 gedatolisib, n=9 gedatolisib+AC; metastasis-free, not overall, survival. — Figure 4G comparison table and caption

Vehicle · Results 3.4; Figure 4A–G and caption; Methods 2.4.1, 2.4.3–2.4.9 and 2.5

AC chemotherapy · Results 3.4; Figure 4A–G and caption; Methods 2.4.1, 2.4.3–2.4.9 and 2.5

Gedatolisib · Results 3.4; Figure 4A–G and caption; Methods 2.4.1, 2.4.3–2.4.9 and 2.5

Gedatolisib plus AC · Results 3.4; Figure 4A–G and caption; Methods 2.4.1, 2.4.3–2.4.9 and 2.5

Seven-day encapsulated breast-tumor mini-PDX assay

Animal study · Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice. [2]

Gedatolisib suppressed the terminal viable-cell growth endpoint in both models. This was a 7-day capsule assay using only two mice per arm, not a tumor-regression, survival or metastasis-prevention experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor-cell growth inhibition in PDX361836TCGI versus saline 85%; P = 0.001[2]
Tumor-cell growth inhibition in PDX362153TCGI versus saline >60%; P = 0.025[2]

Conditions shared by the study groups

Treatment course
7 days
Vehicle
Gedatolisib clinical formulation resuspended in water; saline control. Comparator-specific vehicles described in Animal studies.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline controlSaline for efficacy; pairwise inhibitor comparisonsReference for normalized tumor-cell growth[2]
Gedatolisib
15 mg/kg
Saline for efficacy; pairwise inhibitor comparisons85% TCGI in PDX361836; >60% TCGI in PDX362153[2]
Alpelisib
30 mg/kg
Saline for efficacy; pairwise inhibitor comparisons55% TCGI in PDX361836; not significant in PDX362153[2]
Capivasertib
100 mg/kg
Saline for efficacy; pairwise inhibitor comparisons20% TCGI, not significant, in PDX361836; not significant in PDX362153[2]
Everolimus
2 mg/kg
Saline for efficacy; pairwise inhibitor comparisons60% TCGI in PDX361836; not significant in PDX362153[2]
Saline control
Model: Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice.
Route: Not specified for saline
Frequency: Not specified for saline
Reported limits: Six capsules (3 per mouse × 2 mice) per arm; capsules are nested within mice.
Gedatolisib
Model: Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice.
Route: Intravenous
Frequency: Q4D
Reported limits: Six capsules (3 per mouse × 2 mice) per arm; capsules are nested within mice.
Alpelisib
Model: Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice.
Route: Oral
Frequency: QD
Reported limits: Six capsules (3 per mouse × 2 mice) per arm; capsules are nested within mice.
Capivasertib
Model: Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice.
Route: Oral
Frequency: BID, 4 days on/3 days off
Reported limits: Six capsules (3 per mouse × 2 mice) per arm; capsules are nested within mice.
Everolimus
Model: Two ER-positive breast-cancer mini-PDX models: PDX361836 (PIK3CA/PTEN altered) and PDX362153 (PIK3CA/PTEN wild type), encapsulated cells in female BALB/c nude mice.
Route: Oral
Frequency: QD
Reported limits: Six capsules (3 per mouse × 2 mice) per arm; capsules are nested within mice.
Methods and source locations

Compound reported in the paper: Gedatolisib (PKI-587); Compound label in the paper: gedatolisib

Evidence for the named active compound in the stated model and formulation; no Adooq lot validation or salt/form conversion.

Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Tumor-cell growth inhibition in PDX361836: Six capsules from two mice/arm; two-sided unpaired Student t-test; figure shows mean ± SEM. Gedatolisib versus alpelisib P = 0.054 (not significant). — Results mini-PDX subsection; Figure 7b

Tumor-cell growth inhibition in PDX362153: Six capsules from two mice/arm; two-sided unpaired Student t-test; mean ± SEM. — Results mini-PDX subsection; Figure 7c

Saline control · Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Gedatolisib · Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Alpelisib · Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Capivasertib · Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Everolimus · Figure 7a–c and caption; Results: Analysis of PAM inhibitors in BC mini-PDX mouse models; Methods: Animal studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1197160-78-3
Applications PI3K/mTOR inhibitor
Formula C32H41N9O4
Molecular Weight 615.7
Synonyms PKI587
SMILES
CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 2 mg/mL (3.24 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gedatolisib (PKI-587) Research References

  1. [1] Yusuke Murase, Kenji Hosoya, Takachika Sato, et al. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells Oncology Reports (2022). PMID: 35088890 DOI: 10.3892/or.2022.8272 Source material
  2. [2] Stefano Rossetti, Aaron Broege, Adrish Sen, et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models npj Breast Cancer (2024). PMID: 38839777 DOI: 10.1038/s41523-024-00648-0 Source material
  3. [3] Ryann E Shor, Jinxiang Dai, Sun‐Young Lee, et al. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings Molecular Oncology (2022). PMID: 34058066 DOI: 10.1002/1878-0261.13031 Source material

Publications

1 publication citing this product

  1. Yusuke Murase, .et al. , Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890

Added to your cart

View Cart Checkout
Loading...